TCTR20200306001已完成未知
Ischemia modified albumin (IMA) is associated with peripheral arterial disease and dialysis modality in chronic hemodialysis patients
Ramathibodi hospital, Mahidol university0 个研究点目标入组 210 人开始时间: 2020年3月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •Inclusion criteria included receipt of chronic HD treatments for >2 weeks, age > 15 years and ability to provide valid informed consent. Patients who declined to participate in the study were excluded
排除标准
- •Patients who declined to participate in the study were excluded.
研究者
相似试验
已完成
不适用
The Utility of Ischemia Modified Albumin (IMA) in SepsisSevere SepsisSepsis SyndromeSepsisSystemic Inflammatory Response SyndromeNCT00448968Inverness Medical Innovations150
终止
不适用
The Ischemia Modified Albumin In Diagnosing Ischemic New EventsHeart Disease, IschemicIschemia, MyocardialIschemic Heart DiseaseUnstable AnginaNCT00355992Inverness Medical Innovations1,250
Unknown
不适用
The Role of Ischemia Modified Albumin in Patients With COVID-19COVID-19NCT05286268Larissa University Hospital194
已完成
不适用
Ischemia Modified Albumin in Traumatic Brain InjuryTraumatic Brain InjuryNCT03637101Kasr El Aini Hospital54
已完成
不适用
Ischemia Modified Albumin (IMA) Expression in the Male and Female PopulationGroup IdentificationNCT02894671Istituto Ortopedico Rizzoli100